Setmelanotide
Selective MC4R agonist for rare genetic obesity disorders. Precision medicine peptide targeting melanocortin pathway mutations in leptin-melanocortin signaling deficiencies.
Setmelanotide is a potent and selective melanocortin-4 receptor (MC4R) agonist, an 8-amino acid cyclic peptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH). It is the first FDA-approved therapy for chronic weight management in patients with rare genetic disorders of obesity, including pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), and leptin receptor (LEPR) deficiencies.
| Parameter | Specification |
| CAS | 920014-72-8 |
| Molecular Formula | C₄₉H₆₈N₁₈O₉S₂ |
| Molecular Weight | 1117.32 g/mol |
| Category | GLP-1/Metabolic |
| Purity | ≥99% |
| Status | GMP-compliant, FDA-ready |
| Applications | Genetic obesity (POMC, LEPR, PCSK1 deficiencies), hyperphagia |
| CAS | 920014-72-8 |
|---|---|
| Applications | Appetite Regulation, Genetic Obesity, MC4R Agonist, metabolic syndrome |
Related products
-
Glucagon HCl
CAS: 16941-32-5Applications: Diabetic Emergency, Glycogenolysis, Hypoglycemia Rescue -
Lixisenatide
CAS: 320367-13-3Applications: postprandial glucose control, Short-acting GLP-1, Type 2 diabetes -
Tirzepatide
CAS: 2023788-19-2Applications: Advanced obesity, metabolic syndrome, Type 2 diabetes -
GLP-1 (7-37)
CAS: 106612-94-6Applications: Diabetes Research, GLP-1 Analog Development, metabolic syndrome